FDALabel for drug repurposing studies and beyond

Nat Biotechnol. 2020 Dec;38(12):1378-1379. doi: 10.1038/s41587-020-00751-0.

Authors

Affiliations

¹ National Center for Toxicological Research, US FDA, Jefferson, AR, USA.
² College of Pharmacy, University of Florida, Orlando, FL, USA.
³ Office of Translational Sciences, Center for Drug Evaluation and Research, US FDA, Silver Spring, MD, USA.
⁴ National Center for Toxicological Research, US FDA, Jefferson, AR, USA. Weida.Tong@fda.hhs.gov.

PMID: 33235392
DOI: 10.1038/s41587-020-00751-0

No abstract available

Publication types

Letter

MeSH terms

Drug Development
Drug Discovery
Drug Labeling*
Drug Repositioning*
Humans
United States
United States Food and Drug Administration*